APA (7th ed.) Citation

C, V., M, R., JA, D., H, H., TG, M., A, K., . . . CJ, F. (2026). Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium. Blood cancer journal, 16(1), . https://doi.org/10.1038/s41408-026-01469-z

Chicago Style (17th ed.) Citation

C, Varga, et al. "Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor-T Cell Therapy (CAR-T)-related Hematologic Toxicity in Patients with Relapsed/refractory Multiple Myeloma (RRMM)-real World Experience from the US Multiple Myeloma Immunotherapy Consortium." Blood Cancer Journal 16, no. 1 (2026). https://doi.org/10.1038/s41408-026-01469-z.

MLA (9th ed.) Citation

C, Varga, et al. "Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor-T Cell Therapy (CAR-T)-related Hematologic Toxicity in Patients with Relapsed/refractory Multiple Myeloma (RRMM)-real World Experience from the US Multiple Myeloma Immunotherapy Consortium." Blood Cancer Journal, vol. 16, no. 1, 2026, https://doi.org/10.1038/s41408-026-01469-z.